Business Wire

NY-AQARA

Share
Aqara Adds a Smart Radiator Thermostat to its Product Portfolio

Aqara, a leading provider of smart home products, introduced its Radiator Thermostat E1 to automate hydronic radiators including wall-mounted radiators, towel warmers and even warm floors, making the heating systems smarter for improved energy efficiency and comfort. This radiator thermostat supports most radiator valves with its M30*1.5mm thread connection and the provided adapters for RA, RAV and RAVL valves1. The Aqara Radiator Thermostat E1 is now available on European Amazon stores (France, Germany, Italy, Spain, UK), as well as via selective Aqara retailers in Europe2.

Based on the Zigbee 3.0 protocol, the Thermostat is expected to support the future-proofing Matter standard via an OTA update of the compatible, Zigbee 3.0-based Aqara hub3. The device is also compatible with major ecosystems and voice assistants such as HomeKit/Siri, Alexa, Google Home/Google Assistant, IFTTT, Home Assistant4 and more. Users can be reassured that the Thermostat works with their smart home setups of today and tomorrow.

Unlike many thermostatic radiator valves (TRVs) that rely solely on an internal sensor to measure the room temperature, which can be inaccurate due to the sensor’s proximity to the radiator, the Radiator Thermostat E1 can receive the temperature readings directly from a connected Aqara temperature sensor5 (including in HomeKit), and regulate the radiator based on the actual room temperature to increase comfort. Moreover, when connected to an Aqara Door and Window Sensor, the Thermostat can be configured to stop heating the room when any door or window is left open, in order to reduce energy waste. With the wide range of Aqara devices, users are able to create customized home automation that heats their homes only when it’s needed.

The Aqara Home app also offers various options for radiator automation. A smart schedule can be configured, allowing users to set the desired temperatures for different periods of time throughout the day, for example to set it to 5℃ during the daytime of weekdays when no one is at home, 25℃ for a relaxing evening after work, and 20℃ for a night of comfortable sleep. Geofencing is also possible, so the radiators will heat up the home before the family arrives. Another option is to automate the radiators based on local weather, and the heating will turn on automatically when the local temperature drops below a certain threshold.

Other features of the Radiator Thermostat include:

  • Device grouping: multiple radiators in one room can be synchronized so that they work in a more efficient way, and make it possible to set different temperatures for each room;
  • Multi-home management: in the case of having more than one home, users are able to manage the radiators in each home separately and set up individual automation such as geofencing-based automation;
  • Anti-freeze mode: users can preset a temperature between 5℃ - 15℃ for this mode, and activate the mode easily when they are out of town to conserve energy while reducing the risk of pipe freezing;
  • 12-month battery life: thanks to the Zigbee protocol and the energy-efficient hardware, 2 AA batteries will power the Thermostat for up to one year of use6.

To celebrate the launch, Aqara now offers a 10% discount for the Radiator Thermostat on its European Amazon stores in France, Germany, Italy, Spain and the UK with the promo code TRVE1UKEU. The code will be valid through September 15, 2022.

For more details of the Radiator Thermostat E1, please visit our website.

  1. This thermostat is only compatible with thermostatic valves, while manual, return temperature limiter (RTL) as well as monotube radiator systems are not supported. However in the majority of cases, it is possible to convert the existing radiator valve to a supporting one using an aftermarket adapter. Please consult professional installers or authorized Aqara retailers for more details.
  2. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the local retailer(s) for real time availability.
  3. Matter support may be unavailable by the time of the launch.
  4. Home Assistant support can be achieved using HomeKit Controller integration, which is developed by the Home Assistant community.
  5. Aqara’s Temperature and Humidity Sensor or TVOC Air Quality Monitor is required.
  6. Battery life may vary depending on the usage. The 1-year battery life is calculated based on the assumption of 8 operations per day for a heating season of 165 days and 1 operation every 2 weeks for the rest 200 days.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005022/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye